-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels: Characteristics and Application Prospects of PBMC Mixed Inoculation Models
Author:
InnoModels
Release time:
2024-03-05
In biomedical research, human peripheral blood mononuclear cell (PBMC) models are widely used to simulate human immune responses and disease processes. As an advanced experimental tool, the PBMC hybrid inoculation model of InnoModels Biotechnology has attracted wide attention in the field of immunology research with its unique advantages. In this paper, we will introduce the features of the model of hybrid inoculation of InnoModels Biotechnology PBMC and discuss the prospects of its application.
Model features:
1. Highly simulate the human body environment: By simulating the cellular environment in the human body, the PBMC hybrid inoculation model of InnoModels Biotechnology is able to more realistically reflect the immune response of the human body after pathogen infection or vaccination. This model not only contains a variety of immune cells, but also simulates cell-cell interactions and signaling, thus providing a research platform that is closer to the actual human body.
2. High flexibility: The model can be flexibly adjusted according to the research needs in terms of the types of pathogens to be inoculated, their concentrations and the time of inoculation, in order to more accurately simulate different infection scenarios or immunization protocols. Meanwhile, the model is relatively simple to construct and can be personalized according to laboratory conditions and needs.
3. Highly reproducible: The InnoModels PBMC hybrid inoculation model has a high degree of standardization in operation and high reproducibility of experimental results. This provides researchers with a stable and reliable research tool, which helps to promote the progress of immunology and biomedical fields.
4. Wide range of adaptation: The model is not only suitable for studying the immune mechanism of infectious diseases, but also can be used in many fields such as vaccine development, drug screening and immunotherapy. By adjusting the vaccination conditions and observation indexes, the immune response process under different disease states can be studied in depth.

Application Prospects:
As an advanced biomedical research tool, the PBMC hybrid inoculation model has a broad application prospect. With the continuous development of immunology and biomedicine, the model will play an important role in the following aspects:
1. vaccine development: by simulating the immune response after vaccination, the effectiveness and safety of vaccines can be evaluated, providing strong support for the development of new vaccines.
2. drug screening: using the model, drug candidates with immunomodulatory or anti-infective effects can be screened to provide experimental basis for clinical drug development.
3. immunotherapy research: by intervening the immune cells in the model, the effect and mechanism of different immunotherapy strategies can be studied, providing theoretical support for clinical immunotherapy.
4. Disease mechanism research: By simulating the immune response under different disease states, we can gain a deeper understanding of the pathogenesis and pathological process of diseases, and provide new ideas and methods for disease prevention and treatment.
In summary, with its highly simulated human environment, high flexibility, repeatability and wide range of adaptability, InnoModels Biotechnology PBMC hybrid inoculation model shows great potential and value in the field of biomedical research. With the continuous progress of science and technology and the improvement of experimental methods, the model will play a more important role in promoting the development of immunology and biomedical fields.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd